Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2003

View Archived Issues

New benzisoxazole-based LXR agonists under study at Merck

Novel IMP dehydrogenase inhibitors and their use reported by Celltech R&D

Ajinomoto prepares alpha4 integrin inhibitors

Merck patent covers new mGluR5 antagonists for pain, anxiety and other uses

Bayer presents new p38 kinase inhibitors with potential in COPD therapy

Gruenenthal presents new modulators of IL-12 and IL-10 production

Cetuximab monotherapy in advanced renal cell carcinoma

Intercept Blood System inactivates causative agent of SARS

Causal relationship established between VNS Therapy and depression improvement

European approval recommended for Emtriva

PEG-camptothecin advances for gastric and gastroesophageal junction cancers

Phase III induction trial of Antegren fails to meet primary endpoint

New phase II study evaluates COL-3 in rosacea

Avonex ACT trial commences enrollment

First phase of ONTARGET/TRANSCEND program completed

Biotech Holdings plans postmarketing study for Sucanon in Mexico

Enrollment completed in phase IIb at-home study of PT-141

Diovan approved in Switzerland for ACE inhibitor-intolerant heart failure patients

Sanvar registration dossier accepted for filing by FDA

New phase I trial to evaluate lipid-regulating agent ETC-1001

Potent and selective antitumor activity demonstrated for anti-CD30 antibody-drug conjugate

Telomerase inhibitor GRN-163 advances through preclinical testing

CPMP issues positive opinion for Bondronat for metastatic bone disease

Neurocrine Biosciences initiates phase II trial with NBI-5788 in MS patients

NS-2359 enters phase II testing

FDA approves palonosetron for CINV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...